When a pharmaceutical company expands into new markets, technical documentation is one of the most sensitive areas. Translating a medicine’s summary of product characteristics is not just a linguistic task: it means complying with strict regulations and guaranteeing absolute accuracy.
In this article you will see how to approach the process properly, which mistakes to avoid and how to manage it reliably in international settings.
Why translating medicine SmPCs is a critical process
The summary of product characteristics (SmPC) contains essential information about a medicine: composition, indications, dosage and adverse effects. It is a regulated document that must meet very specific standards in each country.
An incorrect translation can lead to:
- Rejection by health authorities
- Delays in registration processes
- Legal or reputational risks
Unlike other corporate content, there is no room for interpretation here. Every term must be accurate and validated.
Common mistakes when companies translate SmPCs
Using non-specialised translation
One of the most common mistakes is relying on generalist or machine translation without expert review. This usually results in:
- Incorrect terminology
- Literal translations with no clinical context
- Loss of accuracy
Failures of this kind are not unique to the pharmaceutical sector. The same happens in other critical fields, as explained in the article, where a small nuance can have significant consequences.
Failing to adapt the content to local regulations
Translating is not a matter of reproducing the text in another language. Each market requires:
- Specific structures
- Regulated terminology
- Particular formats
An SmPC that is valid in one country may not be accepted in another if it is not properly adapted.
Lack of terminological consistency
In companies operating across several countries, it is common to find:
- Different terms for the same concept
- Inconsistencies between documents
- Misaligned versions
This complicates regulatory processes and creates internal inefficiencies.
How to translate a medicine SmPC properly
Work with specialist translators
The first step is to work with professionals who know the pharmaceutical sector. Command of the language is not enough: you need an understanding of medical terminology and the regulatory context.
This point is crucial when compared with the use of automated tools. As analysed in this article, speed cannot replace accuracy where there are legal or health risks involved.
Build glossaries and translation memories
To guarantee consistency, it is advisable to:
- Define validated terminology glossaries
- Use translation memories
- Centralise linguistic criteria
This keeps documentation consistent across markets and streamlines processes.
Include technical review and validation
An SmPC translation should go through several stages:
- Specialist translation
- Linguistic review
- Validation by medical or regulatory experts
This process is essential to ensure the document meets both linguistic and technical requirements.
Real cases in international companies
Simultaneous launch in several countries
A pharmaceutical company launches a medicine in several European markets at the same time.
Problem:
- Each subsidiary manages the translation independently
- Different terminology in each version
Result: delays in approval and the need to redo the documentation.
Solution: centralise language management and unify terminology criteria.
Integration after a corporate acquisition
A multinational acquires a company with products registered in different countries.
Problem:
- Inconsistent documentation
- Accumulated differences in terminology
- Lack of document control
Solution: a linguistic audit and full standardisation of the SmPCs.
Why a language partner matters in B2B settings
Translating SmPCs is not a one-off task but an ongoing process in international companies.
Working with a specialist partner allows you to:
- Maintain global consistency
- Reduce validation times
- Minimise regulatory risks
- Scale international operations
In this context, translation becomes a strategic asset within the company.
Frequently asked questions
No. The content has to be adapted to the regulatory requirements of the target country, in terminology as well as structure.
Besides the translator, a medical or regulatory expert should be involved to guarantee accuracy.
Tools can help, but they never replace specialist human review in critical documents.
Translating a medicine’s summary of product characteristics is a key process for any company operating internationally. Accuracy, consistency and sector knowledge make the difference between a smooth process and a regulatory problem.
At ALOS we help companies manage this kind of documentation with specialist language solutions. If you need support for your international projects, you can contact our team and design a strategy tailored to your company.